The quarter came in slightly ahead on revenue but below on EPS. Ceribell delivered $28.1 million of revenue versus a published consensus of approximately $27.83 million, while its $0.51 per-share loss was worse than the roughly $0.48 expected loss.
| Metric | Q2 2026 | Q2 2025 | Market expectation |
|---|---|---|---|
| Total revenue | $28.1 million (Financial Highlights) | $21.2 million (Financial Highlights) | ~$27.83 million |
| Gross margin | 92% (Financial Highlights) | 88% (Financial Highlights) | — |
| Net loss | $(19.3) million (Income Statement) | $(13.6) million (Income Statement) | — |
| Net loss per share | $(0.51) (Income Statement) | $(0.38) (Income Statement) | ~$(0.48) |
| Adjusted EBITDA loss | $(9.8) million (Non-GAAP Reconciliation) | $(10.0) million (Non-GAAP Reconciliation) | — |
Underlying demand was better than the headline numbers suggest. Revenue grew 33% year over year, with product revenue up 33% and subscription revenue up 30%, indicating both new account additions and higher usage from existing customers—not just a one-time product shipment effect. The 92% gross margin was also strong, though it benefited partly from tariff refunds, making the full improvement less repeatable (Financial Highlights).
Management raised the full-year revenue outlook, adding a clearer positive surprise. The new $114 million–$117 million range is above the prior $112 million–$116 million range, implying a modest upward reset to expectations rather than a wholesale change in trajectory. The filing attributes the increase to continued account growth and utilization, consistent with the quarter’s revenue performance (2026 Financial Outlook).
Profitability remains the main constraint. Operating expenses rose 37%, substantially faster than revenue, driven by commercial hiring, product-pipeline investment, stock compensation, and patent litigation. As a result, the GAAP net loss widened to $19.3 million, even though adjusted EBITDA loss improved slightly to $9.8 million; the gap reflects $6.0 million of stock compensation and $3.9 million of IP litigation costs excluded from adjusted EBITDA (Income Statement; Non-GAAP Reconciliation).
The net read is modestly favorable versus expectations, but not cleanly so. A small revenue beat, a guidance increase, and slightly improved adjusted EBITDA outweigh the EPS miss, while FDA clearances, the delirium-monitoring reimbursement effective October 1, 2026, and a new credit facility expand the potential growth runway. However, cash and marketable securities fell to $129.3 million from $159.3 million at year-end, and the new facility adds financing capacity rather than demonstrating reduced cash consumption (Balance Sheets; Financial Highlights).
Read the original 8-K on SEC EDGAR ↗